Opendata, web and dolomites

KIT

Kidney Injury Technology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 KIT project word cloud

Explore the words cloud of the KIT project. It provides you a very rough idea of what is the project "KIT" about.

maturity    market    income    samples    69    thorough    validation       transferability    gt    price    technological    regulated    license    standard    poses    inren    elisa    acquire    prognosis    patient    2017    ivd       reference    bio    yield    clinically    economic    aki    commercialization    dismally    huge    people    posing       disease    company    2023    clinical    deadly    2018    smes    kit    manufacturing    international    envisioned    billion    instrument    prototype    tests    royalties    reduce    channels    rate    35    critical    worldwide    gold    vitro    revolutionary    upfront    laid    annual    transfer    health    population    diagnostics    started    diagnostic    yearly    penetration       incidence    renal    human    acute    650    incident    competitors    sought    expenditure    elevated    thereafter    grows    initially    sme    sale    companies    global    handling    patented    128    biomarker    sales    10    marker    capacity    consolidation    unitary   

Project "KIT" data sheet

The following table provides information about the project.

Coordinator
BIO-INREN SL 

Organization address
address: NORBERTO CUESTA DUTARI 39 4 D
city: SALAMANCA
postcode: 37007
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.bio-inren.es
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-11-01   to  2015-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIO-INREN SL ES (SALAMANCA) coordinator 50˙000.00

Map

 Project objective

Bio-inRen has developed and patented a revolutionary biomarker-based diagnostic system for a highly and increasingly incident (>10% yearly) and dismally deadly disease (Acute Renal Failure -AKI) posing a huge global health and economic problem worldwide. Bio-inRen’s diagnostic system is envisioned to 1) change the concept and approach to AKI clinical handling, 2) become a reference diagnostic, 3) reduce AKI incidence (by 2.5-5% initially) and improve patient prognosis, and 4) reduce the elevated cost associated to AKI (1% of their global health expenditure, which will be reduced initially in 650 M € in this 1.35 billion people population). An ELISA-based, clinically useful prototype kit has been developed for measurement of human samples. Clinical validation has started, although Bio-inRen’s system needs thorough clinical validation to acquire technological maturity and transferability, for which Phase I and II SME instrument are necessary, on which all the company’s resources will be laid. As a new concept, Bio-inRen’s technology has no competitors in the market or under development. The In Vitro Diagnostic Market grows at a 7% annual rate and will reach $69.1 billion by 2017. AKI-specific market is estimated at 3.5 M cases and 70 M diagnostic tests of the existing gold standard marker. Because Diagnostics is a global and regulated market, Bio-inRen will license the system to large companies and SMEs in the IVD market with manufacturing capacity and international commercialization channels. Technology transfer is expected by 2018 to yield 1 M € upfront and 5% royalties on sales thereafter. 5% market penetration is sought by 2023. As of today, 5% of 70 M tests poses 3.5 M tests as Bio-inRen’s market (6.4 M tests by 2023 at 7% annual growth rate). At a unitary sale price of 20 €/test, this means 128 M €. 5% royalties will produce a yearly income of 6.4 M € to Bio-inRen, which are critical for the consolidation and growth of the company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More